Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 6/2019

01-08-2019 | Human Papillomavirus | Original Paper

Economic burden of HPV9-related diseases: a real-world cost analysis from Italy

Authors: F. S. Mennini, Gianluca Fabiano, G. Favato, P. Sciattella, P. Bonanni, C. Pinto, A. Marcellusi

Published in: The European Journal of Health Economics | Issue 6/2019

Login to get access

Abstract

Introduction

The objectives of this study were to estimate the economic burden of HPV in Italy, accounting for total direct medical costs associated with nine major HPV-related diseases, and to provide a measure of the burden attributable to HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 infections.

Methods

A cost-of-illness incidence-based model was developed to estimate the incidences and costs of invasive cervical cancer, cervical dysplasia, cancer of the vulva, vagina, anus, penis, oropharyngeal, anogenital warts, and recurrent respiratory papillomatosis (RRP) in the context of the Italian National Health System (NHS). We used data from hospital discharge records (HDRs) of an Italian region and conducted a systematic literature review to estimate the lifetime cost per case, the number of incident cases, the prevalence of HPV9 types. Costs of therapeutic options not included in the diagnosis-related group (DRG) tariffs were estimated through a scenario analysis.

Results

In 2018, the total annual direct costs were €542.7 million, with a range of €346.7–€782.0 million. These costs could increase considering innovative therapies for cancer treatment (range €16.2–€37.5 million). The fraction attributable to the HPV9 genotypes without innovative cancers treatment was €329.5 million, accounting for 61% of the total annual burden of HPV-related diseases in Italy. Of this amount, €135.9 million (41%) was related to men, accounting for 64% of the costs associated with non-cervical conditions.

Conclusions

The infections by HPV9 strains and the economic burden of non-cervical HPV-related diseases in men were found to be the main drivers of direct costs.
Appendix
Available only for authorised users
Literature
1.
Goldstone, S., et al.: Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J. Infect. Dis. 203(1), 66–74 (2011)CrossRefPubMedPubMedCentral
2.
McQuillan, G.M., et al.: Prevalence of HPV in adults aged 18-69: United States, 2011–2014. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Hyattsville, MD (2017)
3.
Favato, G., et al.: A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy. Clin. Ther. 35(7), 904–914 (2013)CrossRefPubMed
4.
5.
Walboomers, J.M., et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189(1), 12–19 (1999)CrossRefPubMed
6.
Chaturvedi, A.K.: Beyond cervical cancer: burden of other HPV-related cancers among men and women. J. Adolesc. Health 46(4 Suppl), S20–S26 (2010)CrossRefPubMed
7.
Koutsky, L.A., Galloway, D.A., Holmes, K.K.: Epidemiology of genital human papillomavirus infection. Epidemiol. Rev. 10, 122–163 (1988)CrossRefPubMed
8.
Armstrong, L.R., Derkay, C.S., Reeves, W.C.: Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch. Otolaryngol. Head Neck Surg. 125(7), 743–748 (1999)CrossRefPubMed
9.
Armstrong, L.R., et al.: Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin. Infect. Dis. 31(1), 107–109 (2000)CrossRefPubMed
10.
Hartwig, S., Baldauf, J.J., Dominiak-Felden, G.: Estimation of the epidemiological burden of HPV-related cancers, precancerous lesions, and genital warts in women and men in Europe: potential additional benefit of a nine-valent compared to first generation HPV vaccines. Papillomavirus Res 1, 90–100 (2015)CrossRefPubMedCentral
11.
12.
13.
14.
Favato, G., et al.: Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases: the BEST study. Med. Care 50(12), 1076–1085 (2012)CrossRefPubMed
15.
16.
17.
Ferrandina, G., et al.: Hospital costs incurred by the Italian National Health Service for invasive cervical cancer. Gynecol. Oncol. 119(2), 243–249 (2010)CrossRefPubMed
18.
Mennini, F.S., et al.: Anti-HPV vaccination: a review of recent economic data for Italy. Vaccine 27(Suppl 1), A54–A61 (2009)CrossRefPubMed
19.
Giorgi Rossi, P., et al.: Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy. BMC Public Health 9, 71 (2009)CrossRefPubMed
20.
Mennini, F.S., et al.: Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol. Oncol. 112(2), 370–376 (2009)CrossRefPubMed
21.
Salute, M.: Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di raibilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. 2013, Pubblicato sulla GURI N. 23 del 28/01/2013 Suppl. n. 8
22.
Merito, M., et al.: Treatment patterns and associated costs for genital warts in Italy. Curr. Med. Res. Opin. 24(11), 3175–3183 (2008)CrossRefPubMed
23.
24.
Mennini, F.S., et al.: Burden of disease of human papillomavirus (HPV): hospitalizations in the Marche and Veneto regions. An observational study. Clin. Drug Investig. 38(2), 173–180 (2018)CrossRefPubMed
25.
26.
Fattore, G.: Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. PharmacoEcon. Ital. Res. Artic. 11(2), 83–93 (2009)CrossRef
27.
Bishai, D., Kashima, H., Shah, K.: The cost of juvenile-onset recurrent respiratory papillomatosis. Arch. Otolaryngol. Head Neck Surg. 126(8), 935–939 (2000)CrossRefPubMed
28.
Hu, D., Goldie, S.: The economic burden of noncervical human papillomavirus disease in the United States. Am. J. Obstet. Gynecol. 198(5), 500e1–500e7 (2008)CrossRef
29.
30.
AIOM, A.: I numeri del cancro in Italia 2017. I.P.S. Editore, Editor (2017)
31.
Serrano, B., et al.: Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur. J. Cancer 51(13), 1732–1741 (2015)CrossRefPubMed
32.
WHO, I., Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human papillomavirus and related cancers in Italy, I. Summary Report, Editor (2017)
33.
Garcia-Espinosa, B., Moro-Rodriguez, E., Alvarez-Fernandez, E.: Genotype distribution of human papillomavirus (HPV) in histological sections of cervical intraepithelial neoplasia and invasive cervical carcinoma in Madrid, Spain. BMC Cancer 12, 533 (2012)CrossRefPubMedPubMedCentral
34.
Hartwig, S., et al.: Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 12, 30 (2012)CrossRefPubMedPubMedCentral
35.
36.
Castellsague, X., et al.: HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J. Natl. Cancer Inst. 108(6), djv403 (2016)CrossRefPubMed
37.
Miralles-Guri, C., et al.: HPV prevalence and type distribution in penile carcinoma. J. Clin. Pathol. 62(10), 870–878 (2009)CrossRefPubMed
38.
Donne, A.J., et al.: The role of HPV type in Recurrent Respiratory Papillomatosis. Int. J. Pediatr. Otorhinolaryngol. 74(1), 7–14 (2010)CrossRefPubMed
39.
Fusconi, M., et al.: Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir. Acta Otorhinolaryngol. Ital. 34(6), 375–381 (2014)PubMedPubMedCentral
40.
Lacey, C.J., Lowndes, C.M., Shah, K.V.: Chap. 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24(Suppl 3), S3/35–S41 (2006)
41.
Briggs, A.H., Claxton, K., Sculpher, M.J.: Decision modelling for health economic evaluation. Handbooks in health economic evaluation series. Oxford University Press, Oxford (2006) (x, 237, ill.; 24 cm)
42.
Favato, G., Vecchiato, R.: Embedding real options in scenario planning: a new methodological approach. Technol. Forecast. Soc. Change 124(November 2017), 135–149 (2017)CrossRef
43.
Brown, B., et al.: An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health 11(5), 791–799 (2008)CrossRefPubMed
44.
Mandic, A., Usaj Knezevic, S., Kapicl, T., Ivkovic: Tissue expression of VEGF in cervical intraepithelial neoplasia and cervical cancer. J BUON 19(4), 958–964 (2014)PubMed
45.
Friedlander, M., Grogan, M., Force, U.S.P.S.T.: Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist 7(4), 342–347 (2002)PubMed
46.
Tewari, K.S., et al.: Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390(10103), 1654–1663 (2017)CrossRefPubMedPubMedCentral
Metadata
Title
Economic burden of HPV9-related diseases: a real-world cost analysis from Italy
Authors
F. S. Mennini
Gianluca Fabiano
G. Favato
P. Sciattella
P. Bonanni
C. Pinto
A. Marcellusi
Publication date
01-08-2019
Publisher
Springer Berlin Heidelberg
Published in
The European Journal of Health Economics / Issue 6/2019
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-019-01044-3

Other articles of this Issue 6/2019

The European Journal of Health Economics 6/2019 Go to the issue

Original Paper

The closer the better: does better access to outpatient care prevent hospitalization?

Original Paper

Health state utilities associated with post-surgical Staphylococcus aureus infections

Original Paper

Impact of unemployment on self-perceived health

Editorial

Assessing capability in economic evaluation: a life course approach?

Original Paper

Moral hazard under zero price policy: evidence from Japanese long-term care claims data

Original Paper

How to make value-based health insurance designs more effective? A systematic review and meta-analysis